{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabeprazole+sodium",
    "query": {
      "intervention": "Rabeprazole sodium"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 70,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rabeprazole+sodium&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-13T08:57:41.929Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01759875",
      "title": "Effects of Gastric pH on the Pharmacokinetics of Atazanavir",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ritonavir-boosted Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir-boosted Atazanavir plus Rabeprazole",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 8,
      "start_date": "2013-01",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2015-04-28",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01759875"
    },
    {
      "nct_id": "NCT00132496",
      "title": "Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease"
      ],
      "interventions": [
        {
          "name": "rabeprazole sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "12 Years to 16 Years"
      },
      "enrollment_count": 111,
      "start_date": "2005-08",
      "completion_date": "2006-07",
      "has_results": true,
      "last_update_posted_date": "2009-12-03",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 25,
      "location_summary": "Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more",
      "locations": [
        {
          "city": "Longmont",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "New Port Richey",
          "state": "Florida"
        },
        {
          "city": "Snellville",
          "state": "Georgia"
        },
        {
          "city": "Hoffman Estates",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00132496"
    },
    {
      "nct_id": "NCT00658632",
      "title": "Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole sodium",
          "type": "DRUG"
        },
        {
          "name": "Esomeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1397,
      "start_date": "2008-02",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2016-05-04",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 85,
      "location_summary": "Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sherwood",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00658632"
    },
    {
      "nct_id": "NCT03130556",
      "title": "A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Glasdegib",
          "type": "DRUG"
        },
        {
          "name": "High Fat, High Calorie Meal",
          "type": "OTHER"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-05-01",
      "completion_date": "2017-07-21",
      "has_results": false,
      "last_update_posted_date": "2017-08-01",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03130556"
    },
    {
      "nct_id": "NCT00222170",
      "title": "Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Reflux"
      ],
      "interventions": [
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "19 Years to 79 Years"
      },
      "enrollment_count": 24,
      "start_date": "2005-05",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2009-05-08",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00222170"
    },
    {
      "nct_id": "NCT01237353",
      "title": "Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pharmacodynamic"
      ],
      "interventions": [
        {
          "name": "betaine hydrochloride",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 6,
      "start_date": "2011-03",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2013-07-02",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01237353"
    },
    {
      "nct_id": "NCT00838526",
      "title": "Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux Disease (GERD)"
      ],
      "interventions": [
        {
          "name": "Rabeprazole ER",
          "type": "DRUG"
        },
        {
          "name": "Ranitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 240,
      "start_date": "2008-08-31",
      "completion_date": "2009-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 4,
      "location_summary": "Moline, Illinois",
      "locations": [
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00838526"
    },
    {
      "nct_id": "NCT00649493",
      "title": "Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rabeprazole Sodium Tablets 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Aciphex® Tablets 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2003-05",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2024-04-23",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00649493"
    },
    {
      "nct_id": "NCT01153659",
      "title": "A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "E3810",
          "type": "DRUG"
        },
        {
          "name": "Aciphex (rabeprazole)",
          "type": "DRUG"
        },
        {
          "name": "Nexium (esomeprazole)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 90,
      "start_date": "2010-07",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "Oklahoma City, Oklahoma",
      "locations": [
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01153659"
    },
    {
      "nct_id": "NCT00648349",
      "title": "Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Rabeprazole Sodium Delayed-Release Tablets 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Aciphex® Delayed-Release Tablets 20 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mylan Pharmaceuticals Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2003-05",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-13T08:57:41.929Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00648349"
    }
  ]
}